%0 Online Multimedia %A Jo, Eun %A Lee, Young %A Lee, Hyunjoo %A Park, Jae %A Park, Hyojun %A Choi, Yoon-La %A Hong, Doopyo %A Kim, Sung %D 2019 %T Additional file 11: of Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells %U https://springernature.figshare.com/articles/presentation/Additional_file_11_of_Combination_therapy_with_c-met_inhibitor_and_TRAIL_enhances_apoptosis_in_dedifferentiated_liposarcoma_patient-derived_cells/8186276 %R 10.6084/m9.figshare.8186276.v1 %2 https://springernature.figshare.com/ndownloader/files/15255713 %K Human recombinant TRAIL %K C-met inhibitor %K Liposarcoma %K DR5 %K C-met receptor %K DR5 dependent apoptosis %K Combination treatment %X Figure S9. c-Met and rhTRAIL receptor expression levels in DDLPS. PDCs. c-Met inhibitor PF upregulated expression levels of c-Met in DDLPS PDCs. The expression levels of DcR1, DcR2, DR4, DR5, and c-Met were analyzed by flow cytometry after DMSO (vehicle: shaded gray histogram) and PF (5 μM: bold black open histogram) treatment for 48 h, as shown in the upper column (a). c-Met expression levels in LPS224, LPS246, 11GS-013, 11GS-079, 11GS-099, 11GS-106 and 11GS-076 cells were analyzed by flow cytometry (b). (PPTX 513 kb) %I figshare